Strategic partnerships ChromaTan is expanding through integrations and collaborations, most notably the March 2025 integration with Landmark Bio, signaling a channel-friendly growth path. This presents sales opportunities to position complementary biosciences service providers and contract development organizations that can co-offer streamlined purification solutions.

Affordable therapeutics With a focus on cost-effective production and purified biologics, there is a clear opportunity to target biopharma manufacturers seeking to reduce resin consumption and downtime. Highlight how the columnless continuous chromatography platform can lower production costs and shorten time-to-patient delivery.

NIH funding leverage Recent NIH IIB grant funding of two million dollars indicates investor and grant alignment around innovative purification tech. Sales discussions can align with potential customers pursuing grant-eligible projects or with grant consultants to accelerate adoption and pilot programs.

Process development system The launch of the Kascade BioRMB Process Development System and emphasis on continuous countercurrent chromatography suggests opportunities to engage early-stage biotech, CMOs, and manufacturers needing rapid process development, screening, and scale-up capabilities.

Leadership and growth New CEO appointment and active fundraising activity (Series A history and recent funding) indicate a growth trajectory and a receptive market approach from leadership. This is a signal to initiate outreach around strategic collaborations, co-development deals, and long-term supply arrangements.